Abstracts of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications”
نویسنده
چکیده
s of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications” Abstracts of the NIH-FDA Conference 188s of the NIH-FDA Conference 188
منابع مشابه
Existing technology for target validation and expression analysis
biomarkers is an important goal for the pharmaceutical industry.Validation of innovative, highly specific and practical biomarkers would dramatically accelerate research on the etiology, pathophysiology, progression and prognosis of diseases. It would also facilitate the development of pharmacotherapies, including the identification of treatment responses, in terms of responders and non-respond...
متن کاملبینش پشت استفاده از بیومارکرهای IFN-G، IL-2، IL-4 و IL-10به‌عنوان نقاط پایانی جانشین برای ابتلا به بیماری-های پوستی ناشی از مواجهه با گاز خردل
Background and Objective: Here,it is tried to assess an insight behind using IFN-G,IL-2,IL-4,and IL-10 biomarkers as potential surrogate endpoints for skin diseases caused by exposure to mustard gas. Potentially,a biomarker is a valid surrogate if assessment of the treatment effect based on surrogate endpoint leads to the same result based on true clinical endpoint. Materials and Methods: In S...
متن کاملWho? What? Where? A snapshot of Nuclear Medicine Research Presentations from recent ANZSNM conferences in Australia and New Zealand.
Objective(s): The aims of this study were to: 1) discover location (by city) of contributors to poster and oral presentations at recent ANZSNM conferences; 2) determine the nuclear medicine themes most commonly explored; 3) establish institutions producing the highest number of oral and poster abstracts and 4) determine publication rates of conference abstracts to full...
متن کاملVascular biomarkers and surrogates in cardiovascular disease.
Cardiovascular biomarker research efforts have resulted in the identification of new risk factors and novel drug targets, as well as the establishment of treatment guidelines. Government agencies, academic research institutions, diagnostic industries, and pharmaceutical companies all recognize the importance of biomarkers in advancing therapies to improve public health. In drug development, bio...
متن کاملGlaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.
The 2010 NEI-FDA Glaucoma Clinical Design and Endpoints Symposium was a follow-up to a similar March 2008 public meeting where the glaucoma research community, National Eye Institute (NEI) of the National Institutes of Health (NIH), and Food and Drug Administration Center for Drug Development and Research (FDA CDER) convened to discuss adopting new endpoint measures for assessing glaucoma thera...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 14 شماره
صفحات -
تاریخ انتشار 1998